<?xml version="1.0" encoding="UTF-8"?>
<akn:akomaNtoso xmlns:akn="http://docs.oasis-open.org/legaldocml/ns/akn/3.0"><akn:act><akn:meta><akn:identification source="#cosilico"><akn:FRBRWork prescriptive="true" authoritative="true"><akn:FRBRuri value="/akn/us/usc/21/360eee–1" /><akn:FRBRdate date="2025-12-31" name="retrieval" /><akn:FRBRauthor href="#us-congress" /><akn:FRBRcountry value="us" /></akn:FRBRWork><akn:FRBRExpression><akn:FRBRuri value="/akn/us/usc/21/360eee–1/eng@2025" /><akn:FRBRdate date="2025-12-31" /><akn:FRBRauthor href="#cosilico" /><akn:FRBRlanguage language="en" /></akn:FRBRExpression><akn:FRBRManifestation><akn:FRBRuri value="/akn/us/usc/21/360eee–1/eng@2025/main.xml" /><akn:FRBRdate date="2025-12-31" /><akn:FRBRauthor href="#cosilico" /></akn:FRBRManifestation></akn:identification></akn:meta><akn:body><akn:section eId="sec_360eee_1"><akn:num>360eee–1</akn:num><akn:heading>Requirements</akn:heading><akn:content><akn:p>§ 360eee–1. Requirements(a) In general(1) Other activitiesEach manufacturer, repackager, wholesale distributor, and dispenser shall comply with the requirements set forth in this section with respect to the role of such manufacturer, repackager, wholesale distributor, or dispenser in a transaction involving product. If an entity meets the definition of more than one of the entities listed in the preceding sentence, such entity shall comply with all applicable requirements in this section, but shall not be required to duplicate requirements.


(2) Initial standards(A) In generalThe Secretary shall, in consultation with other appropriate Federal officials, manufacturers, repackagers, wholesale distributors, dispensers, and other pharmaceutical distribution supply chain stakeholders, issue a draft guidance document that establishes standards for the interoperable exchange of transaction information, transaction history, and transaction statements, in paper or electronic format, for compliance with this subsection and subsections (b), (c), (d), and (e). In establishing such standards, the Secretary shall consider the feasibility of establishing standardized documentation to be used by members of the pharmaceutical distribution supply chain to convey the transaction information, transaction history, and transaction statement to the subsequent purchaser of a product and to facilitate the exchange of lot level data. The standards established under this paragraph shall take into consideration the standards established under section 355e of this title and shall comply with a form and format developed by a widely recognized international standards development organization.


(B) Public inputPrior to issuing the draft guidance under subparagraph (A), the Secretary shall gather comments and information from stakeholders and maintain such comments and information in a public docket for at least 60 days prior to issuing such guidance.


(C) PublicationThe Secretary shall publish </akn:p></akn:content><akn:subsection eId="subsec_360eee_1_a"><akn:num>(a)</akn:num><akn:heading>In general</akn:heading><akn:content><akn:p>(a) In general</akn:p></akn:content></akn:subsection><akn:subsection eId="subsec_360eee_1_b"><akn:num>(b)</akn:num><akn:heading>Manufacturer requirements</akn:heading><akn:content><akn:p>(b) Manufacturer requirements</akn:p></akn:content></akn:subsection><akn:subsection eId="subsec_360eee_1_c"><akn:num>(c)</akn:num><akn:heading>Wholesale distributor requirements</akn:heading><akn:content><akn:p>(c) Wholesale distributor requirements</akn:p></akn:content></akn:subsection><akn:subsection eId="subsec_360eee_1_d"><akn:num>(d)</akn:num><akn:heading>Dispenser requirements</akn:heading><akn:content><akn:p>(d) Dispenser requirements</akn:p></akn:content></akn:subsection><akn:subsection eId="subsec_360eee_1_e"><akn:num>(e)</akn:num><akn:heading>Repackager requirements</akn:heading><akn:content><akn:p>(e) Repackager requirements</akn:p></akn:content></akn:subsection><akn:subsection eId="subsec_360eee_1_f"><akn:num>(f)</akn:num><akn:heading>Drop shipments</akn:heading><akn:content><akn:p>(f) Drop shipments</akn:p></akn:content></akn:subsection><akn:subsection eId="subsec_360eee_1_g"><akn:num>(g)</akn:num><akn:heading>Enhanced drug distribution security</akn:heading><akn:content><akn:p>(g) Enhanced drug distribution security</akn:p></akn:content></akn:subsection><akn:subsection eId="subsec_360eee_1_h"><akn:num>(h)</akn:num><akn:heading>Guidance documents</akn:heading><akn:content><akn:p>(h) Guidance documents</akn:p></akn:content></akn:subsection><akn:subsection eId="subsec_360eee_1_i"><akn:num>(i)</akn:num><akn:heading>Public meetings</akn:heading><akn:content><akn:p>(i) Public meetings</akn:p></akn:content></akn:subsection><akn:subsection eId="subsec_360eee_1_j"><akn:num>(j)</akn:num><akn:heading>Pilot projects</akn:heading><akn:content><akn:p>(j) Pilot projects</akn:p></akn:content></akn:subsection></akn:section></akn:body></akn:act></akn:akomaNtoso>